SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 80.71 CNY | -3.05% |
|
-1.79% | -38.21% |
Summary: Shanghai MicroPort Endovascular MedTech Co., Ltd.
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Highlights: Shanghai MicroPort Endovascular MedTech Co., Ltd.
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses: Shanghai MicroPort Endovascular MedTech Co., Ltd.
- The company's enterprise value to sales, at 4.76 times its current sales, is high.
Ratings Chart: Shanghai MicroPort Endovascular MedTech Co., Ltd.
Source: Surperformance
| Composite Fundamentals | Composite Valuation | Composite Momentum | Capi. ($) | ||
|---|---|---|---|---|---|
| 1.44B | |||||
| 140B | |||||
| 13.64B | |||||
| - | 6.94B | ||||
| 6.07B | |||||
| 5.84B | |||||
| 3.51B | |||||
| 2.42B | |||||
| - | 1.85B | ||||
| - | 1.45B | ||||
| Average | 18.33B | ||||
| Weighted average by Cap. |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 688016 Stock
- Ratings Shanghai MicroPort Endovascular MedTech Co., Ltd.
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition